Alcoholism is a chronic illness that affects millions of individuals globally. Despite the presence of a range of effective therapies, not much is known about this problem, which is characterized by uncontrolled drinking.
Prior studies suggest that when psychedelics are administered in conjunction with psychotherapy, they may effectively help to manage addiction. Despite these promising findings, minimal studies have looked into LSD’s influence on reward-linked behaviors in mice models.
Mice models are often used to study alcoholism as they afford scientists insights into the behavioral and neurological changes that occur with the chronic use of alcohol. Now a new study has found that LSD can be used to reduce alcohol binge-drinking for a short period of time, as observed in rodent models.
University of Helsinki’s Lauri Elsilä, the study author, stated that the researchers’ objective was to find out if the lasting effects observed when a single dose of a psychedelic was administered to reduce alcohol drinking as demonstrated in prior studies in human participants would also be observed in a rodent model. For their research, the scientists examined LSD’s impact on male mice that had been introduced to alcohol over a four-week period. The alcohol was available for two hours a day, on four days every week. In the fifth week, the rodents were treated with LSD or a saline solution then allowed to drink alcohol.
The researchers discovered that mice that received the LSD treatment exhibited decreased alcohol intake in comparison to those that received the saline solution, which suggests that LSD had an effect on the consumption of alcohol.
In their report, the investigators stated that they observed no further ethanol intake reduction effects on the days that followed once the rodents were given alcohol. They added that the possibility of studying molecular mechanisms with tools that weren’t available in people was one of the many advantages of using mice models in psychedelic studies. The researchers also called attention to the fact that while mice models had helped researchers to better understand alcoholism, they were not ideal substitutes for human subjects.
This is in addition to highlighting the need to conduct more studies, in an effort to completely understand the effects psychedelics have on alcoholism in humans. The study’s findings were reported in the “Journal of Psychopharmacology.” Other researchers involved in the study include Esa R. Korpi, Anni-Maija Linden, Alvar Martti, Emma Enbergand and Juliana Harkki.
The findings of this particular study highlight why psychedelics companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) conduct extensive research and envision psychedelics being used in clinical settings in order to ensure patients enjoy long-term benefits from the treatments they undergo.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
